iBio Inc

iBio Inc a biotechnology company provides contract development and manufacturing services to collaborators and thirdparty customers in the United States The company operates in two segments Biopharmaceuticals and Bioprocessing Its lead therapeutic candidate is IBIO100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis The company is also developing vaccine candidates comprising IBIO200 and IBIO201 which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2 and IBIO400 for the treatment of classical swine fever In addition it is developing recombinant proteins for third parties on a catalog and custom basis and offers a range of process development manufacturing filling and finishing and bio analytic services iBio Inc has a license agreement with Planet Biotechnology Inc to develop therapeutics for infectious diseases collaboration agreement with The Texas AM University System for the development of coronavirus disease 2019 vaccine candidates license agreement with the University of Natural Resources and Life Sciences Vienna and collaboration agreement with CCPharming Ltd The company is headquartered in Bryan Texas